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mend that smokers be strongly advised to quit, and should be offered help in doing
so. The most effective smoking-cessation interventions combine behavioural support
with pharmacotherapies. For smokers who do not wish to use nicotine replacement
treatments, bupropion is a safe and effective non-nicotine alternative first-line
treatment. Nortriptyline and clonidine have demonstrated efficacy in aiding smoking
cessation, but are regarded as second-line therapies. A number of other non-nicotine
treatments show promise, but more data are required before these can be
recommended in assisting smokers to stop.
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H. McRobbie et al.1204been proven to modify the course of airways
obstruction, and can result in improving pulmonary
function, decreasing respiratory symptoms, and
decreasing acute respiratory tract infections.2
International COPD guidelines recommend that
smokers be strongly advised to quit, and should
be offered help in doing so.3
Most smokers say they want to stop, and about
two-thirds will make an attempt each year. How-
ever, many will choose to make an unaided quit
attempt; a method that has only a small chance of
long-term success.4 The primary reason why many
smokers find it difficult to quit is because of their
dependence on nicotine. Tobacco smoke provides
rapid delivery of nicotine to the central nervous
system, where it facilitates the release of a number
of neurotransmitters, such as dopamine and nora-
drenaline.5 In dependent smokers, nicotine depri-
vation precipitates a withdrawal syndrome,
consisting of symptoms such as irritability, low
mood, poor concentration, and urges to smoke that
can undermine a smokers’ attempt to quit.6
Two smoking-cessation medications are in com-
mon use: nicotine replacement therapy (NRT), of
which there are six different products, and bupro-
pion (Zyban). NRT acts by replacing some of the
nicotine smokers would have received from their
cigarettes, and in doing so reduces the severity of
withdrawal symptoms. NRT approximately doubles
the chance of long-term abstinence (odds ratio
[OR] ¼ 1.74; 95% CI: 1.64–1.86),7 although the
absolute success rate depends upon the intensity
of the additional support provided and the type of
smoker being treated.8 Although effective, this
medication is no magic cure, and at least 70% ofTable 1 Summary of criteria for entry into Cochrane re
cessation.
Study types Randomised trials with adequate
Participants Current smokers and recent quitt
Intervention Use of a non-nicotine pharmacoth
Most interventions combined pha
the treatment with placebo or an
Outcome measures Abstinence from smoking measure
Wherever possible the strictest c
was given to continuous, or susta
self-reported abstinence. Some r
validated abstinence to be includ
Where biochemical verification o
whose self-reports were validated
One review included studies that
baseline.10
Intention-to-treat analysis was us
Participants lost to follow-up wer
*Clonidine review required at least 12 weeks of follow-up.13*Op
looked at withdrawal symptoms.16smokers who try to quit using NRT relapse within a
year.9 A large number of studies examining the
efficacy of various non-nicotine pharmacotherapies
for smoking cessation have been published. This
paper attempts to summarise the findings of
systematic reviews of these treatments.Method
We searched the Cochrane Library, PubMed, and
PsychLit databases for systematic reviews of non-
nicotine pharmacotherapies for smoking cessation.
We have relied mainly on systematic reviews
contained in the Cochrane Library, as these have
clear and strict criteria for entry into the reviews
(Table 1). Seven reviews of non-nicotine treat-
ments for smoking cessation have been published in
the Cochrane Library: antidepressants, anxiolytics,
clonidine, lobeline, mecamylamine, opioid antago-
nists, and silver acetate.10–16 On the basis of
conclusions from these reviews, and smoking-
cessation guidelines,17,18 we allocated treatments
to one of three categories: (1) first-line medica-
tions for smoking cessation; (2) second-line medi-
cations for smoking cessation; and (3) medications
not currently recommended for smoking cessation.First-line medications for smoking
cessation
Bupropion, an atypical antidepressant, is the first,
and, so far, the only non-nicotine treatment
licensed for smoking cessation.views of non-nicotine pharmacotherapies for smoking
control group.
ers.
erapy to aid smoking cessation or to prevent relapse.
rmacotherapy with behavioural support and compared
alternative smoking-cessation aid.
d for at least 6 months after starting treatment.*
riteria for abstinence outcome were used. Preference
ined, abstinence rates and biochemical verification of
eviews required studies to report biochemically
ed.12,15,16
f abstinence was undertaken, only those participants
were included as abstainers.
measured cigarette reduction by 50% or less of
ed wherever possible.
e counted as smokers.
ioid antagonists review included short-term follow-ups that
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sants for smoking cessation, as a strong association
exists between smoking and depression. A higher
prevalence of smoking exists among people who
have, or have had a history of, depression.19
Smokers who are depressed find it more difficult
to quit, some smokers become depressed when
they stop smoking, and post-cessation depression is
related to relapse.20,21 However, not all antide-
pressants have been shown to be helpful for
smoking cessation.4,10
Bupropion is presumed to help smokers quit
through its ability to inhibit the neuronal reuptake
of dopamine and noradrenaline, both important in
nicotine dependence and withdrawal. It may also
help through its action as a non-competitive
inhibitor of the nicotinic acetylcholine receptor,
and perhaps by way of its effect on serotonin
reuptake.22 Although the precise mechanism by
which this medication aids smoking cessation
remains uncertain, bupropion has been proven to
increase abstinence rates10,18,22,23 and reduce the
severity of withdrawal symptoms experienced by
smokers when they abstain.24–28
Two pivotal outcome studies were published in
the late 1990s. The first compared the effect of
three different daily doses (100, 150, and 300mg)
with placebo.24 Results showed a linear effect of an
increasing dose on point-prevalence cessation,
although no significant difference was found be-
tween 150 and 300mg per day at 12 months follow-
up. The second major study randomised smokers to
receive either bupropion (300mg/day), 21mg/24 h
nicotine patch, both bupropion and patch, or
placebo.26 The 1-year continuous abstinence rates
were 18%, 10%, 23%, and 6%, respectively. All active
treatments were significantly better than placebo,
and bupropion was better than patch alone. There
was no added advantage of using a combination
regimen compared with bupropion alone.
Since these studies, a number of other studies
examining the efficacy of bupropion have been
published. One Cochrane review10 identified a total
of 24 that met their inclusion criteria. Nineteen
studies, which included more than 4000 smokers,
looked exclusively at the efficacy of bupropion
compared with placebo. All studies used adjunctive
behavioural support. The meta-analysis showed
that, compared with placebo, bupropion approxi-
mately doubled long-term abstinence rates
(OR ¼ 2.06; 95% CI: 1.77–2.40).
The efficacy of bupropion has also been exam-
ined in smokers with smoking-related disease, a
population typically more dependent and therefore
harder to treat. People with stable cardiovascular
disease treated with bupropion, compared withplacebo, achieved higher 1-year continuous absti-
nence rates (22% vs. 9%).29 When used in smokers
with mild to moderate COPD, bupropion was
associated with significantly higher abstinence
rates at 6 months (16% vs. 9%)28 but not at 1 year
(10% vs. 9%).10
Its use in preventing smoking relapse has also
been examined.25,30 The results of one study
investigating the use of bupropion, compared with
placebo, for a year showed no difference in
continuous abstinence rates between groups at 1
or 2 years after quitting.25 Another study showed no
advantage of using bupropion over placebo for
preventing relapse in patients successfully quitting
smoking using a nicotine patch.30 Therefore,
evidence currently available suggests there is little
benefit for using bupropion long-term to prevent
relapse.10
Few studies have compared bupropion with other
smoking-cessation medications. In one of the
pivotal studies mentioned earlier, bupropion was
more effective than the nicotine patch.26 Combin-
ing NRT and bupropion significantly increased 1-
year outcome compared with patch alone (23% vs.
10%). However, more recent studies have not
confirmed these results.10 Further data are needed
on this issue.
Bupropion is a safe treatment when used
correctly. Contraindications should be checked
when prescribing this medication (Table 2). In
addition, some precautions need to be considered.
Smokers with a predisposition to seizures should
not take bupropion unless the benefit of smoking
cessation outweighs any risks associated with using
the medication.31 Bupropion, however, has been
found safe to use in smokers with stable cardiovas-
cular disease, without adverse effects on blood
pressure or heart rate.29
Bupropion undergoes hepatic metabolism, pri-
marily by isoenzyme CYP2B6. Therefore, other
drugs that affect this enzyme (e.g. cimetidine,
sodium valproate and cyclophosphamide) may
affect bupropion metabolism. Bupropion inhibits
the activity of CYP2D6, and so there may be a
reduced rate of metabolism of drugs such as beta-
blockers and Type 1C antiarrhythmics. A dose
reduction in these medications may be required.32
Bupropion is marketed for smoking cessation
under its trade name Zyban, and is available in
150mg sustained-release tablets. The recom-
mended treatment regimen is described in Table
2. A reduced dose may be required in elderly
people, people with diabetes, and smokers with
renal or hepatic impairment.32 Understandably,
some smokers may be concerned that they are
receiving a less effective treatment if they are
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Table 2 Prescribing information for bupropion HCL SR 150mg tablets (Zyban).
Contraindications10,32
 Smokers under 18 years of age
 Pregnant women
 Hypersensitivity to bupropion
 A current or previous seizure disorder
 Tumour of the central nervous system
 A current or previous diagnosis of bulimia or anorexia nervosa
 Severe hepatic cirrhosis
 Concomitant use of bupropion and monoamine oxidase inhibitors
 A history of bipolar disorder
 Withdrawal from alcohol or benzodiazepines
Precautions10,32
It is recommended that a risk–benefit assessment be undertaken before prescribing bupropion to patients with
other risk factors for seizures.36 Risk factors for seizures include the following:
 Medications that lower seizure threshold (e.g. antidepressants, antipsychotics, antimalarials, quinolones,
sedating antihistamines, systemic corticosteroids, theophylline, tramadol)
 Current use of stimulants and anorectics
 Alcohol abuse
 History of head injury
Dosage32
 Days 1–6: one tablet daily; from day 7: one tablet twice a day, keeping at least 8 h between each dose.
 The quit date should be set between 8 and 14 days after. The smoker continues to smoke as normal up to their
quit date and then stop completely, aiming not to have a single puff after this.
 A total course of 120 tablets should be prescribed, but it is sensible to give a smaller quantity initially so there
is no wastage if the smoker experiences adverse events, or does not manage to achieve abstinence.
Dosage adjustments
 Elderly: 150mg once daily is recommended.
 Hepatic/renal insufficiency: 150mg once daily is recommended.
 Diabetes: If diet controlled, the standard dose can be prescribed. If well controlled with insulin or oral
hypoglycaemics, prescribe 150mg once daily. If poorly controlled use NRT
Adverse effects22,32
 Common (occurrence41:100): dry mouth, insomnia, nausea, headache.
 Rare (occurrence41:10,000 ando1:1000): seizure, severe hypersensitivity reaction.
H. McRobbie et al.1206taking a reduced dose. Presently, only two studies
have investigated the efficacy of different
doses.24,33 When results were pooled, there was
no added advantage in 1-year abstinence rates
between 300 and 150mg per day.10
Insomnia and dry mouth are common side-
effects, experienced by more than one-third of
users of bupropion.22 A rash may also occur, and,
as with many other medications, there is also a
small risk of a severe allergic reaction.32 Another
adverse effect to note is an approximate 1:1000
risk of seizure.32 This is similar to some other
antidepressants, including fluoxetine.34 Following
its launch in the UK in 2000, the media reported a
number of deaths and serious adverse events in
people using bupropion. Post-marketing surveil-
lance in the UK estimated that about 540,000smokers had received bupropion within the first 2
years.35 Over this period, there were 60 fatal
adverse events; however, bupropion was not
implicated as a causative factor, and, in many
cases, an underlying smoking-related disease was
identified as the cause of death. One hundred and
eighty-four cases of seizure were reported, with
50% of these having risk factors for or past history
of seizures.
Overall, the benefit of bupropion-aided smoking
cessation outweighs the risks of drug-related
adverse events. Smoking cessation guidelines in
the UK and USA recommend bupropion as a safe and
effective medication for those who are able to take
it and wish to use it.17,18,23 For the best chance of
success, it should be used in combination with
intensive behavioural support.
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cessation
Nortriptyline
As previously discussed, there is a good rationale
for using antidepressants in aiding smoking cessa-
tion. Nortriptyline is a tricyclic antidepressant that
inhibits the reuptake of noradrenaline and seroto-
nin.4,5,36 It is presumed to act through its nora-
drenergic mechanism, reducing the severity of
withdrawal symptoms. Other hypotheses for its
smoking-cessation properties include its anxiolytic
effects and anticholinergic side-effects, such as dry
mouth, which may make cigarettes less desirable.37
The Cochrane review identified six randomised-
controlled trials that met their inclusion criteria.10
These included trials that compared nortriptyline
with placebo as well as combining nortriptyline and
comparing it with nicotine patch. Altogether, when
pooled, the OR was 2.14 (95% CI: 1.49–3.06).
Pooling the results from the four studies that
compared nortriptyline with placebo only, nortrip-
tyline is found to at least double the chance of
long-term abstinence (OR ¼ 2.79; 95% CI:
1.70–4.59).10 An added advantage of nortri-
ptyline is that it is a generic medication and
inexpensive.
The treatment regimen involves a starting dose
of 25mg/day, increasing gradually over a period
of some 3 weeks to a target dose of 75–100mg/day,
which is generally needed to reach a thera-
peutic level of 50–50 ng/ml.37,38 The quit date is
usually set once therapeutic levels of the drug
have been reached; this may take 10–28 days.18
The treatment period is typically 12 weeks, with
the dose tapered after this. There is limited
evidence of benefit for extending treatment past
3 months.10
The primary concern with using nortriptyline,
like other tricyclic antidepressants, is its adverse
cardiovascular effects. It is contraindicated in
those who have experienced a recent myocardial
infarction or arrhythmias.36 Severe liver disease is
another contraindication. In addition, there are a
number of precautions to note, such as use in
people with cardiac disease, a history of epilepsy or
psychosis, and women who are pregnant or breast-
feeding.
Nortriptyline has a number of common side-
effects (e.g. dry mouth, light-headedness, shaki-
ness, and blurred vision).39 Urinary retention,
constipation, sexual difficulties, and seizure risk
are also reported.36 In addition to these, an
overdose of nortriptyline is commonly fatal.Given that other effective medications for
smoking cessation are readily available, nortripty-
line is currently regarded as a second-line therapy.
Furthermore, it is not FDA approved for smoking
cessation.18Clonidine
Clonidine is an alpha-2 adrenoceptor agonist that
reduces sympathetic activity by decreasing nora-
drenaline release. It is generally used as an
antihypertensive and for prevention of recurrent
migraine, but has also been used to treat opioid and
alcohol dependence.5,36 Clonidine has been shown
to ameliorate the symptoms of tobacco with-
drawal, and, in some studies, increase abstinence
rates.13
The Cochrane review identified a total of 21
studies investigating its use for smoking cessation.
However, these were of variable quality, many with
only short-term follow-up. Only six studies met the
inclusion criteria, and the pooled results showed an
OR of 1.89 (95% CI: 1.30–2.74). This is comparable
with the efficacy of NRT and bupropion.7,10 Un-
fortunately, the adverse effects associated with
this medication, such as postural hypotension,
dizziness and dry mouth, makes its use less
desirable. In addition, clonidine causes sedation,
although this might be of some benefit to those who
experience more intense symptoms of tobacco
withdrawal.13 Depression, sleep disturbance and
constipation are also reported, yet these are also
classic symptoms of nicotine withdrawal,6,40 and
therefore it is difficult to ascertain which of the
two is the causal agent. Patients with a history of
depression or occlusive peripheral vascular disease
should avoid using clonidine.
If clonidine is to be used for smoking cessation,
then treatment should be started 2–3 days before
quitting, allowing time to reach steady state
concentration. It has also been used in combi-
nation with NRT to help manage withdrawal.
Clonidine can be taken orally or through a
transdermal patch. Oral doses typically start with
0.1mg/day, and then are gradually increased, up to
0.4mg/day. The transdermal doses that have been
given are between 0.1 and 0.3mg/day. The treat-
ment period is usually short, given over the first
3–4 weeks after quitting when withdrawal sym-
ptoms are most intense. After this, the dose is
reduced over several days, which is particularly
important to avoid hypertensive crisis and hypo-
glycaemia in people with hypertension and diabetes,
respectively.13,18
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for smoking cessation
Other tricyclic antidepressants
As well as nortriptyline, other tricyclic antidepres-
sants, such as doxepin and imipramine, have been
investigated for aiding smoking cessation. The
Cochrane review identified only one small short-
term study for doxepin.10 Although it suggested
that doxepin might reduce urges to smoke, the
study failed to show a significant effect on
abstinence. Further research is needed with larger
samples and longer-term follow-up before ruling
out this antidepressant. A small, short-term,
follow-up study of imipramine failed to find an
effect.10
Monoamine oxidase inhibitors
Smoking is known to inhibit monoamine oxidase A
and B.41 Monoamine oxidase inhibitors (MAOIs),
such as selegiline, lazabemide and moclobemide,
may aid smoking cessation through their ability to
inhibit dopamine metabolism.
Selegiline is a selective MAO-B inhibitor com-
monly used to treat Parkinson’s disease. A number
of small randomised-controlled trials have sug-
gested that this medication might alleviate with-
drawal symptoms and improve outcome.42–44
However, no systematic reviews have been under-
taken.
Moclobemide has been examined in one long-
term trial, which found a significant effect on
smoking cessation at 6 months, but not at 1 year,
compared with placebo.45 More recently, the same
investigator conducted an exploratory trial of
lazabemide, finding that it increased short-term
abstinence compared with placebo.46 However, the
study had to be terminated prematurely, as there
were reports of liver toxicity from studies investi-
gating this drug for other purposes.
Selective serotonin reuptake inhibitors
Five long-term follow-up studies of three different
selective serotonin reuptake inhibitors (SSRIs)
were identified by the Cochrane review. Three
examined the efficacy of fluoxetine, and, although
one showed a significant short-term effect,
none demonstrated any long-term benefit. Only
one trial was conducted for paroxetine, which
included a follow-up at 6 months, and again
showed short-term benefit only. Finally, a study
of sertraline found no effect on 6-month abstinencerates compared with placebo. Pooling the results
of these studies, the estimated OR is 0.90
(95% CI: 0.68–1.18), concluding that the current
research does not support using SSRIs for smoking
cessation.10
Other antidepressants
As well as bupropion, two other atypical antide-
pressants have been reviewed. Tryptophan in-
creases serotonin, which leads to an expectation
that it might reduce withdrawal symptoms. How-
ever, the only published study showed no effect of
this medication. Venlafaxine, a serotonin and
noradrenaline reuptake inhibitor, has been exam-
ined in two studies, neither finding any beneficial
effect.10
Mecamylamine
Mecamylamine is a nicotine antagonist originally
used to lower blood pressure through its ability to
reduce cholinergic activity. It was hypothesised
that it may reduce urges to smoke by blocking the
rewarding effect of nicotine, and be most effective
when combined with NRT. One Cochrane review15
identified two studies that met the inclusion
criteria. Although the results were promising, they
need to be replicated in larger long-term follow-up
randomised-controlled trials. Until further evi-
dence is available, mecamylamine is not recom-
mended for use.15
Lobeline
Lobeline, a partial nicotine agonist, has been
promoted as a smoking-cessation aid since the
1930s, and was readily available over the counter in
the USA. However, early studies had poor metho-
dology and, because of the lack of good efficacy
data, it was banned by the FDA in 1993.14 A
Cochrane review has been undertaken but, owing
to the lack of good quality trials, it concluded that
there is currently no evidence to suggest that
lobeline is effective in helping smokers stop.14
Anxiolytic medications
Medications used for treating anxiety have been
examined as possible smoking-cessation aids. The
rationale for their use is two-fold: firstly, they may
be able to moderate any anxiety experienced as a
withdrawal symptom, and, secondly, these medica-
tions increase dopamine, serotonin and noradrena-
line, which play important roles in nicotine
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number of short-term trials are inconsistent, and,
in general, suggest that anxiolytics may have little
effect on smoking cessation. One Cochrane sys-
tematic review of anxiolytics11 identified just one
trial each for diazepam, meprobamate, metoprolol
and oxprenolol, and two for buspirone that met the
inclusion criteria.
Buspirone is an atypical anxiolytic, and is the
most researched of the group. It is believed to act
through its serotonergic and dopaminergic activity,
and is non-sedating and non-addicting. However,
there seems to be no clear effect on withdrawal
symptoms, and pooled results from two long-term
studies comparing buspirone with placebo showed
no benefit of using buspirone for smoking cessation
(OR ¼ 0.71; 95% CI: 0.34–1.48).11
Diazepam and meprobamate have not been
found to aid smoking cessation. Three beta-block-
ers have been examined (propanolol, metoprolol,
and oxprenolol), but overall there is little evidence
for their effectiveness. There are no good long-
term studies of ondansetron, a 5-HT3 antagonist
thought to affect the reinforcing properties of
nicotine. However, two short-term trials found no
effect on abstinence or withdrawal symptoms.11
The Cochrane review11 proposes that the ratio-
nale for using anxiolytics might be an out-of-date
assumption. The role of anxiety in cessation may
have been overplayed, as anxiety seems to de-
crease rather than increase after cessation.47
Therefore, the rationale for the use of anxiolytics
is questionable.Opioid antagonists
Opioid antagonists, such as naloxone and its longer-
acting formulation naltrexone, are used in the
treatment of other chemical dependencies (e.g.
opioids, cocaine and alcohol). The rationale for
using opioid antagonists in treating tobacco depen-
dence comes from the principle that endogenous
opioids might play a part in the reinforcing effects
of nicotine.48
In the 1980s, several studies were published
reporting the effect of naloxone on smoking
behaviour. Although some showed that it resulted
in a reduction of cigarette consumption compared
with placebo, others did not demonstrate any
effect.16 Conflicting results also exist for the effect
of naltrexone on smoking behaviour.49
The Cochrane review identified only two studies
that provided long-term abstinence data. The
results of both studies failed to demonstrate a
significant effect of naltrexone at 6 months. Whenthe results of each were pooled, the OR was 1.34
(95% CI: 0.49–3.63). The conclusion made by the
authors was that an effect of naltrexone could not
be ruled out, but, on the basis of results seen in
these two studies, no clear recommendations could
be made on the clinical use of this medication for
smoking cessation.16Silver acetate
Silver acetate has been used as a form of aversion
therapy for smoking cessation. Smokers are in-
structed to use the product, which comes in the
form of chewing gum, spray or lozenges, on a
regular basis. When used in combination with
smoking, an unpleasant metallic taste is produced,
thus making smoking less desirable.
A small number of studies have investigated the
effect of this substance with mixed results. How-
ever, one Cochrane review12 shows no advantage of
silver acetate on abstinence rates compared with
placebo (OR ¼ 1.05; 95% CI: 0.63–1.73). In addi-
tion, argyrism (silver deposition) is an adverse
effect that needs to be avoided. It is recommended
that the user should not exceed a total dose of
756mg. This limits the length of time silver acetate
can be used.12Other non-nicotine pharmacotherapies
A number of other non-nicotine pharmacotherapies
are being investigated for use in smoking cessation,
but the relevant literature has not been included in
systematic reviews. Glucose has been shown to
reduce withdrawal and increase short-term absti-
nence rates.50 Drugs that may reduce the reward-
ing effects of nicotine may be useful; for example,
rimonabant, a selective cannabinoid receptor (CB1)
antagonist,52 and baclofen, a GABA receptor
agonist.52 A nicotine vaccine has been developed,
based on the hypothesis that if nicotine can be
stopped from reaching the brain it will not be able
to exert its central effects.53 Medications acting via
the dopaminergic pathways have also been exam-
ined. Bromocriptine, a dopamine agonist, has been
shown to reduce cigarette smoking.54 The dopa-
mine precursor, levodopa, had no effect on with-
drawal or abstinence in one study.55 Finally,
varenicline, a partial agonist of the nicotinic
receptor, is said to reduce withdrawal and increase
abstinence compared with placebo.51 Some of
these medications look promising, but more require
evidence before becoming generally recognised
effective treatments for smokers.
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Nicotine has various actions within the central
nervous system, and several neurochemical path-
ways mediate nicotine withdrawal. A number of
non-nicotine medications acting at different points
in these pathways have been examined for their
potential in aiding smoking cessation.
Antidepressants have generally received the
most attention. Two medications of this cate-
gory are proven to help smokers quit. Bupropion
is backed by the greatest amount of evidence
for its effectiveness. Nortriptyline, although re-
garded as effective, is seen as a treatment
second to bupropion and NRT. It has side-effects
typical for tricyclic antidepressants, such as
dry mouth and blurred vision, and also has a
less safe cardiovascular profile compared with
bupropion.
The only other medication known to significantly
increase long-term cessation rates is clonidine. Like
nortriptyline, it has some unpleasant side-effects,
and its efficacy is no greater than those of
bupropion and NRT. It is not approved by the FDA
as a smoking-cessation treatment, and is currently
recommended as second-line treatment. However,
further study of the effect of this medication is
warranted.
The remainder of medications subjected to
systematic review failed to show any long-term
benefit from their use. Anxiolytics are not helpful
for smoking cessation or for reducing tobacco
withdrawal symptoms, and therefore are not
currently recommended. Substances such as
silver acetate and lobeline are of little to no
benefit, and smokers would be best advised to
use one of the recognised first-line treat-
ments. Although there may be some underlying
beneficial effect of drugs such as naltrexone and
mecamylamine, there is currently not enough
evidence that demonstrates this beyond reasonable
doubt.
The field of smoking cessation is rapidly evolving,
and there is a need to find medications that will
help increase the number of long-term ex-smokers.
It remains to be seen if drugs such as baclofen and
bromocriptine will significantly influence cessation
rates. Exciting new developments include vareni-
cline, rimonabant and the nicotine vaccine. More
data on these medications are likely to appear in
the near future.
Medication to help in stopping smoking should be
accompanied, where possible, by behavioural sup-
port. This has been shown to increase the likelihood
of successful outcomes, with the more intensive
the support the greater the abstinence rates.8 Ifavailable, smokers should be referred to local
smoking-cessation services. These provide good
value for money, and offer the best chance of
success.17 These services are especially important
for those smokers with smoking-related disease
who are typically more dependent.Practice points
 Bupropion is a non-nicotine pharmacother-
apy currently recommended as a first-line
treatment that approximately doubles the
chances of quitting smoking. It is currently
the only licensed alternative to NRT
 The benefit of bupropion outweighs the risk
of drug-related adverse events, and it
should be available to all that are eligible.
For the best chance of success, it should be
used in combination with intensive beha-
vioural support
 Nortriptyline and clonidine are not routinely
used in smoking-cessation services, but
could be considered in smokers who have
not responded to conventional treatments
 Protocols should be put in place to effec-
tively help smokers to stop. This should
include referral to specialist smoking-cessa-
tion servicesResearch directions
 Studies of bupropion have mostly used
adjunctive intensive behavioural support.
Trials using bupropion with minimal, or no,
support are warranted
 Potential future non-nicotine medical
therapies, such as glucose, rimonabant,
baclofen, nicotine vaccine, bromocriptine,
and varenicline require further study and
incorporation into systematic reviews
 Given the burden associated with COPD,
and relative lack of effective smoking-
cessation interventions in smokers with this
disease, further research is urgent and
should be prioritised
 There is good rationale for using pharma-
cotherapies such as mecamylamine, nal-
trexone, SSRIs and MAOIs, and, although
there is little current evidence for their
effectiveness, they might deserve further
investigation before being discarded as
potential smoking-cessation aids
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